Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

M. E. Pavel; E. Baudin; K. E. Öberg; J. D. Hainsworth; M. Voi; N. Rouyrre; M. Peeters; D. J. Gross; J. C. Yao

doi:10.1093/annonc/mdz222

Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

M. E. Pavel, E. Baudin, K. E. Öberg, J. D. Hainsworth, M. Voi, N. Rouyrre, M. Peeters, D. J. Gross, J. C. Yao

Résultats de recherche: Contribution à un journal › !!Comment/debate

4 Citations (Scopus)

Résumé

The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

langue originale	Anglais
Pages (de - à)	2010
Nombre de pages	1
journal	Annals of Oncology
Volume	30
Numéro de publication	12
Les DOIs	https://doi.org/10.1093/annonc/mdz222
état	Publié - 1 déc. 2019
Modification externe	Oui

Accès au document

10.1093/annonc/mdz222

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Pavel, M. E., Baudin, E., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. C. (2019). Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). Annals of Oncology, 30(12), 2010. https://doi.org/10.1093/annonc/mdz222

Pavel, M. E. ; Baudin, E. ; Öberg, K. E. et al. / Corrigendum : Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). Dans: Annals of Oncology. 2019 ; Vol 30, Numéro 12. p. 2010.

@article{a698f3ec4e9145048eab67d99fc6f3ee,

title = "Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)",

abstract = "The following funding information has been added: {"}This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. {"}.",

author = "Pavel, {M. E.} and E. Baudin and {\"O}berg, {K. E.} and Hainsworth, {J. D.} and M. Voi and N. Rouyrre and M. Peeters and Gross, {D. J.} and Yao, {J. C.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1093/annonc/mdz222",

language = "English",

volume = "30",

pages = "2010",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "12",

}

Pavel, ME, Baudin, E, Öberg, KE, Hainsworth, JD, Voi, M, Rouyrre, N, Peeters, M, Gross, DJ & Yao, JC 2019, 'Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)', Annals of Oncology, VOL. 30, Numéro 12, p. 2010. https://doi.org/10.1093/annonc/mdz222

Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). / Pavel, M. E.; Baudin, E.; Öberg, K. E. et al.
Dans: Annals of Oncology, Vol 30, Numéro 12, 01.12.2019, p. 2010.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193)

AU - Pavel, M. E.

AU - Baudin, E.

AU - Öberg, K. E.

AU - Hainsworth, J. D.

AU - Voi, M.

AU - Rouyrre, N.

AU - Peeters, M.

AU - Gross, D. J.

AU - Yao, J. C.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

AB - The following funding information has been added: "This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672. ".

UR - http://www.scopus.com/inward/record.url?scp=85077402628&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz222

DO - 10.1093/annonc/mdz222

M3 - Comment/debate

C2 - 31406974

AN - SCOPUS:85077402628

SN - 0923-7534

VL - 30

SP - 2010

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N et al. Corrigendum: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (Annals of Oncology (2017) 28:7 (1569-1575) DOI: 10.1093/annonc/mdx193). Annals of Oncology. 2019 déc. 1;30(12):2010. doi: 10.1093/annonc/mdz222